x
CME-Tagline

Live Q&A: The Epidemic Within the Pandemic: Managing Complications in Populations with Obesity

CMEO Webcast

Premiere Date: Wednesday, August 4, 2021

This activity offers CE credit for:

  1. Physicians (CME)
  2. Pharmacists (ACPE)
  3. Other

All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™

Credit Expiration Date: Thursday, August 4, 2022

Faculty


Robert F. Kushner, MD, MS,  DABOM Robert F. Kushner, MD, MS, DABOM 
Professor, Departments of Medicine and Medical Education
Northwestern University Feinberg School of Medicine
Chicago, IL

Statement of Need

Obesity is increasingly recognized as a multi-causal chronic disease that leads to structural and physiological abnormalities and functional impairments. Despite the growing prevalence and substantial burden of obesity in terms of health-related quality of life (HRQoL), healthcare utilization, and healthcare costs, obesity remains underdiagnosed and undertreated. The recent recognition that obesity is associated with increased risk of morbidity and mortality with coronavirus disease 2019 (COVID-19) shines a light on the fact that obesity is characterized by higher prevalence of physiologic alterations, such as chronic inflammation and impaired respiratory function, when compared to the non-obese state.

This live question and answer session is your opportunity to ask questions based on the CME Outfitters Live and OnDemand where expert faculty focus on the pathophysiological features of obesity that influence weight loss, guidelines for screening, diagnosis, and patient counseling, and how to assess efficacy and safety of available and emerging therapies for long-term treatment of obesity.. To view the full activity ahead of this live Q&A, click here.

Learning Objectives

At the end of this CE activity, participants should be able to:

  • Identify pathophysiological features of obesity that influence weight loss and maintenance.
  • Apply guidelines for screening, diagnosis, and patient counseling for obesity and obesity-related disorders.
  • Assess efficacy and safety of available and emerging therapies for long-term treatment of obesity.

The following learning objectives pertain only to those requesting CNE credit:

  • Identify pathophysiological features of obesity that influence weight loss and maintenance.
  • Summarize guidelines for screening, diagnosis, and patient counseling for obesity and obesity-related disorders.
  • Describe the efficacy and safety of available and emerging therapies for long-term treatment of obesity.

Financial Support

Supported by an educational grant from Novo Nordisk, Inc.

Target Audience

Primary care physicians, endocrinologists, nurse practitioners, PAs, nurses, and pharmacists

Credit Information

CME Credit (Physicians):
CME Outfitters, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

CME Outfitters, LLC, designates this live activity for a maximum of .5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

CPE Credit (Pharmacists):
ACPE CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. .5 contact hour (0.05 CEUs). Universal Activity Number:
Live: 0376-0000-21-108-L01-P

Type: knowledge-based

Note to Nurse Practitioners: Nurse Practitioners can apply for AMA PRA Category 1 Credit™ through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit™ from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.

Note to PAs: PAs may claim a maximum of .5 Category 1 credits for completing this activity. NCCPA accepts AMA PRA Category 1 Credit™ from organizations accredited by ACCME or a recognized state medical society.

Credit request forms and activity evaluations must be completed online (requires free account activation), and participants can print their certificate or statement of credit immediately. This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit https://www.cmeoutfitters.com/privacy-and-confidentiality-policy

Disclosure Declaration

It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.

Dr. Kushner reports that he receives research support from Epitomee Medical. He is a consultant for Novo Nordisk and WW International, Inc.

Warren Beckman (planning committee) has no disclosures to report.

Evan Luberger (planning committee) has no disclosures to report.

Jan Perez (planning committee) has no disclosures to report.

Sharon Tordoff (planning committee) has no disclosures to report.

Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.

Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.

Questions about this activity? Call us at 877.CME.PROS (877.263.7767).


This document was last modified on:

TVQ-134-080421-68